Oncology - Myeloproliferative Dz News & Articles

Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.

On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

D Scott Cunningham MD, PhD
Site Editor, MDLinx
Markers of obesity and inflammation in postmenopausal breast cancer

Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage

Smartest Doc Challenge
MDLinx
Melanoma Clinical Pearls

MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools

MDLinx Top Read
MDLinx
Running from that pile of unread journals?

New!	>> Find out who is the Smartest Doc in Oncology!

Articles

Latest (3) Full Text Articles (139) Focus on Bone

Ranked, sorted, and summarized by MDLinx editors from the latest literature

Topics:

1 Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes Clinical Cancer Research, May 24, 2013 Clinical Article

2 Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction Hematology, May 24, 2013 Clinical Article

3 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 24, 2013 Clinical Article

Prior Articles

4 Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma British Journal of Haematology, May 23, 2013 Clinical Article

5 Very long lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment European Journal of Haematology, May 23, 2013

6 Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients Clinical Cancer Research, May 22, 2013

7 Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction Hematology, May 22, 2013 Clinical Article

8 Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma Full Text OncoTargets and Therapy, May 21, 2013 Review Article Clinical Article

9 Therapeutic enhancement of ER stress with Insulin Like Growth Factor 1 (IGF-1) sensitizes myeloma cells to proteasomal inhibitors Clinical Cancer Research, May 20, 2013 Clinical Article

10 Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy British Journal of Haematology, May 20, 2013 Clinical Article

11 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 20, 2013 Clinical Article

12 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 16, 2013 Clinical Article

13 IRF4 promotes cell proliferation by JNK pathway in multiple myeloma Medical Oncology, May 15, 2013 Clinical Article

14 A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease Clinical Cancer Research, May 14, 2013

15 In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Clinical Cancer Research, May 14, 2013 Clinical Article

16 Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma British Journal of Cancer, May 10, 2013 Clinical Article

17 TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity British Journal of Haematology, May 10, 2013 Clinical Article

18 Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales The European Journal of Health Economics, May 10, 2013 Clinical Article

19 CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Leukemia, May 9, 2013 Clinical Article

20 Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma Biology of Blood and Marrow Transplantation, May 9, 2013 Clinical Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease

» Test your knowledge. Take the Smartest Doc challenge today!

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.

Read the article summary

HCC risk increased in patients with AIDS

As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.

Read the article summary

RAB25 is a prognostic marker for ovarian cancer

As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Autologous retransplantation for patients with recurrent multiple myeloma Cancer, April 15, 2013

2 Alcohol consumption and risk of lymphoid and myeloid neoplasms: Results of the Netherlands cohort study International Journal of Cancer, April 4, 2013

3 Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment American Journal of Hematology, April 22, 2013

4 Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis Clinical Cancer Research, April 1, 2013

5 Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leukemia and Lymphoma, March 25, 2013

6 Proteasome inhibitors in acute leukemia Expert Review of Anticancer Therapy, March 26, 2013

7 New Strategies in the Treatment of Multiple Myeloma Clinical Cancer Research, April 1, 2013

8 Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Chinese Journal of Cancer Research, April 16, 2013 Free full text

9 Potent antimyeloma activity of a novel ERK5/CDK inhibitor Clinical Cancer Research, April 8, 2013

10 Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States Journal of Clinical Oncology, April 11, 2013

11 Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma Clinical Cancer Research, April 9, 2013

12 Lenalidomide in multiple myeloma—a practice guideline Current Oncology, April 23, 2013 Free full text

13 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 9, 2013 Free full text Clinical Guideline

14 The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis British Journal of Haematology, March 6, 2013

15 Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome Clinical Cancer Research, April 23, 2013

16 Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma Clinical Cancer Research, March 5, 2013

17 Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: a study from the Italian Bone Marrow Donor Registry Biology of Blood and Marrow Transplantation, March 29, 2013

18 Histone deacetylase inhibitors in the treatment for multiple myeloma International Journal of Hematology, March 14, 2013

19 Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma Leukemia, April 15, 2013

20 SH2B3 (LNK) mutations from Myeloproliferative Neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F British Journal of Haematology, April 19, 2013

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Oncology - Myeloproliferative Dz News & Articles

Articles

Prior Articles

Clinical Pearls in Oncology

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

HCC risk increased in patients with AIDS

RAB25 is a prognostic marker for ovarian cancer

Most Popular Oncology Articles

Other Topics in Oncology